About: William C. Gruber

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: William C. Gruber Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

American physician-scientist, pediatrician, business executive

Attributes	Values
rdf:type	Item
owl:sameAs	William C. Gruber
description	باحت (ary) American physician-scientist, pediatrician, business executive (en)
rdfs:label	William C Gruber (nl) William C. Gruber (en) William C. Gruber (es) William C. Gruber (sq)
skos:prefLabel	William C Gruber (nl) William C. Gruber (en) William C. Gruber (es) William C. Gruber (sq)
name	William C Gruber (nl) William C. Gruber (en) William C. Gruber (es) William C. Gruber (sq)
Scopus author ID	wds:Q104936760-5ec2fc83-4cbb-578a-a26b-95b7ad97db8c
Scopus author ID	7101809290
given name	wds:Q104936760-47272ec3-4175-dc81-c200-90a2a87c3c20 wds:Q104936760-74C3B68B-C000-41A5-838E-EF467E2D98F4
given name	William C.
instance of	wds:Q104936760-36ED2CAA-AC05-4772-8B40-4BC5B0F50CE3
instance of	Homo sapiens
Google Knowledge Graph ID	wds:Q104936760-7AD42B4F-2F69-448E-88CC-8AA1D94EAAB0
Google Knowledge Graph ID	http://g.co/kg/g/11ht1zp_nn
Google Knowledge Graph ID	/g/11ht1zp_nn
Semantic Scholar author ID	wds:Q104936760-957b81d1-47bf-c465-0c52-5248b67e5508
Semantic Scholar author ID	2063759
skos:altLabel	William Gruber (en) Bill Gruber (en) W. Gruber (en)
occupation	wds:Q104936760-ab41911f-4b8d-fd3f-ba05-5c606bb115bd wds:Q104936760-ef5233f5-4879-30bf-efd7-e0feb8c2c5ba wds:Q104936760-f786565a-4ad3-da83-c090-922a361b0852
employer	wds:Q104936760-460c62a2-4d5b-414c-5ebb-b8e6a137905e wds:Q104936760-88bc13ad-4f23-9102-e41a-2f8fea7ff69c wds:Q104936760-ca9cfc3a-4674-b7d2-0c5b-a448d05551dd
sex or gender	wds:Q104936760-CC2C3A98-B1B0-4759-A425-28B6883386B3
country of citizenship	wds:Q104936760-05531fe8-4e69-ff4b-ec44-194ba26a9e8a
educated at	wds:Q104936760-6ee348b4-44d5-ea1b-2818-e1bb917f0f4c wds:Q104936760-d9273e55-4f80-bf16-d3b2-7ef2f1a869ec
family name	wds:Q104936760-2fdb8bd7-4e65-5121-cc79-8280993d4c89
occupation	physician-scientist pediatrician business executive
employer	Vanderbilt University School of Medicine Pfizer Wyeth
sex or gender	male
country of citizenship	United States of America
educated at	Baylor College of Medicine Rice University
family name	Gruber
ORCID iD	wds:Q104936760-565bf14a-4c43-7e88-924b-2f5218b300d6
ORCID iD	https://orcid.org/0000-0002-6518-4547
ORCID iD	0000-0002-6518-4547
is about of	William C. Gruber https://www.wikidata.org/wiki/Special:EntityData/Q104936760 William C. Gruber
is author of	Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines Evaluation of anatomic changes in young children with natural rotavirus infection: is intussusception biologically plausible? Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines The role of live influenza vaccines in children An open-label randomized clinical trial of prophylactic paracetamol coadministered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus toxoid, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, a Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software